Skip to main content
Top
Published in: Rheumatology International 8/2019

01-08-2019 | Echocardiography | Cohort Studies

The factors affecting the disease course in Kawasaki disease

Authors: Elif Arslanoglu Aydin, Ilker Ertugrul, Yelda Bilginer, Ezgi Deniz Batu, Hafize Emine Sonmez, Selcan Demir, Zehra Serap Arici, Erdal Sag, Dursun Alehan, Seza Ozen

Published in: Rheumatology International | Issue 8/2019

Login to get access

Abstract

The aim of this study was to review the characteristics of patients with Kawasaki disease (KD) from Turkey and to assess the performance of the Kobayashi score (KS), Harada score (HS), Formosa score (FS), Egami score (ES) and other parameters in predicting intravenous immunoglobulin (IVIG) resistance and coronary artery involvement (CAI) in the Turkish population. Patients who were diagnosed as being in the acute phase of KD at Hacettepe University Faculty of Medicine (Ankara, Turkey) between June 2007 and January 2016 reviewed retrospectively, and those between January 2016 and February 2018 reviewed prospectively, were included in this cohort study. A total of 100 patients with KD were included in this study. Statistical Package for Social Sciences for Windows 22.0 (SPSS Inc, Chicago, IL, USA) was used for statistical analysis. Eighty-five patients (85%) responded to IVIG treatment, whereas 15 (5 female, 10 male) were IVIG resistant. CAI was detected in echocardiography at diagnosis in 31 (31%) (9 female; 22 male) patients. For predicting IVIG resistance, KS, ES, FS, and HS had sensitivity of 82.1%, 26.7%, 30.8%, 69.2% and specificity of 35.7%, 94%, 51.2%, 45.8%, respectively. For the association with CAI occurrence, the sensitivities were 17.2%, 3.3%, 35.7%, 70.4% and the specificities were 78.5%, 88.4%, 49.3%, 49.3% for the aforementioned scores, respectively. The multivariate analysis showed white blood cell (WBC) count [Odd’s ratio (OR) 4.1; 95% confidence interval (CI) 1.26–13.23; p = 0.019] and hematocrit (OR 3.8; 95% CI 1.15–12.4; p = 0.028), as independent predictors of CAI while gamma-glutamyl transferase (GGT) level (OR 5.7; 95% CI 1.73–27.51; p = 0.018) was detected as the only independent predictor of IVIG resistance. This is the first study from Turkey in KD to evaluate the association of the scoring systems for IVIG resistance and CAI. The risk scoring systems in KD did not predict the risk for IVIG resistance and were not associated with CAI in Turkish population.
Appendix
Available only for authorised users
Literature
10.
go back to reference Kobayashi T, Inoue Y, Morikawa A (2008) Risk stratification and prediction of resistance to intravenous immunoglobulin in Kawasaki disease. Nihon Rinsho 66(2):332–337PubMed Kobayashi T, Inoue Y, Morikawa A (2008) Risk stratification and prediction of resistance to intravenous immunoglobulin in Kawasaki disease. Nihon Rinsho 66(2):332–337PubMed
11.
go back to reference Harada K (1991) Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatr Jpn 33(6):805–810CrossRefPubMed Harada K (1991) Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatr Jpn 33(6):805–810CrossRefPubMed
21.
32.
go back to reference Lin MT, Wu MH (2017) The global epidemiology of Kawasaki disease: review and future perspectives. Glob Cardiol Sci Pract 2017(3):201720 Lin MT, Wu MH (2017) The global epidemiology of Kawasaki disease: review and future perspectives. Glob Cardiol Sci Pract 2017(3):201720
Metadata
Title
The factors affecting the disease course in Kawasaki disease
Authors
Elif Arslanoglu Aydin
Ilker Ertugrul
Yelda Bilginer
Ezgi Deniz Batu
Hafize Emine Sonmez
Selcan Demir
Zehra Serap Arici
Erdal Sag
Dursun Alehan
Seza Ozen
Publication date
01-08-2019
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 8/2019
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-019-04336-2

Other articles of this Issue 8/2019

Rheumatology International 8/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.